Likarda

Likarda is a private, revenue-generating biotech company founded in 2012 that operates as a technology platform and services partner. Its patented Core-Shell Spherification® (CSS®) hydrogel encapsulation platform is designed to protect therapeutic payloads, enable controlled release, and improve outcomes for cell therapies, biologics, and small molecules. The company has built a portfolio of branded solutions (e.g., ViscoCell™, EnduraCell™, LiberaCell™, NovoSphere™) with demonstrated preclinical success and is scaling its capabilities, including launching proprietary equipment and an AI-driven formulation platform in 2025. Likarda's business model centers on partnering with and providing enabling technologies to other therapeutic developers.

Proprietary Core-Shell Spherification® (CSS®) hydrogel encapsulation platform for cells, biologics, and small molecules, enabling controlled release, protection, and improved viability. Augmented by an AI-driven Predictive Polymer Analytics™ platform for formulation design.

Likarda competes with other drug delivery and cell encapsulation companies, such as Sigilon Therapeutics (acquired by Lilly) and ViaCyte (now part of Vertex) in encapsulated cell therapy, and various firms in hydrogel-based delivery. Its differentiation lies in the tunable core-shell architecture, broad applicability across payload types, and recent integration of AI for formulation.